TMCnet News
Atrial Fibrillation Therapeutics Pipeline Review, H2 2017 - Research and MarketsThe "Atrial Fibrillation - Pipeline Review, H2 2017" report has been added to Research and Markets' offering. Atrial Fibrillation - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Atrial Fibrillation (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Atrial Fibrillation (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Atrial Fibrillation and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical andDiscovery stages are 1, 1, 3, 2, 8 and 2 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 2 and 1 molecules, respectively. Key Topics Covered:
For more information about this report visit https://www.researchandmarkets.com/research/hz25zx/atrial
View source version on businesswire.com: http://www.businesswire.com/news/home/20170829005622/en/ |
